Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$658.00K$658.00K−89.9% vs Q1 2021 Net Income-$21.32M-$21.32MN/M vs Q1 2021 EPS Diluted-$0.56-$0.56N/M vs Q1 2021 Operating Income-$21,350,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
Free Cash Flowderived$34,388,000N/M Margins · derivedOperating margin-3244.7%−2851.1 pt vs Q1 2021
Net margin-3240.0%−2907.0 pt vs Q1 2021
ended Mar 31, 2022 · filed May 4, 2022 · 34 d after period end